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ABSTRACT 
CYSTEINE DIOXYGENASE: THE IMPORTANCE OF KEY RESIDUES AND 
INSIGHT INTO THE MECHANISM OF THE METAL CENTER 
 
MAY 2008 
JONATHAN H. LEUNG, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Michael J. Maroney 
 
 Cysteine dioxygenase (CDO) is a non-heme iron enzyme that can be found in 
mammalian tissue. It is mainly localized in the liver but is also present in the brain, 
kidney, and adipose tissue. CDO converts cysteine to cysteine sulfinic acid, which is the 
first step in cysteine metabolism in the human body. CDO contains a novel cofactor 
located near the metal binding site that is present in another enzyme, galactose oxidase, 
where it is essential for redox function. This suggests that the linkage may play an 
important role in CDO as well. The cofactor consists of Y157 and C93. Mutation of the 
C93S causes a drop in activity to 57.1% and a mutation of the Y157F causes a drop to 
8.1%. The metal center was studied using XAS revealing that the addition of cysteamine, 
an activator of CDO, changes the conformation of the binding site significantly. CDO 
differs from the rest of the cupin super family in that it does not contain a 2-his-1-
carboxylate binding motif but rather the carboxylate is replaced with another histidine. A 
mutation of one of the binding residues, H140D, caused the enzyme to be non-active. 
Also the mechanism of the CDO was studied by conducting activity assays with various 
 v
inhibitors and activators that yielded contradicting results with previously published 
work. 
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CHAPTER 1 
CYSTEINE DIOXYGENASE 
1.1 Introduction to Cysteine Dioxygenase 
Cysteine dioxygenase (CDO) catalyzes the reaction of cysteine to cysteine 
sulfinic acid (CSA) by adding molecular oxygen to the thiol of cysteine (Figure 1.1). 
This reaction is the first step in the cysteine catabolic pathway. CDO plays a key role 
in maintaining intracellular sulfur concentrations. As such, CDO is mainly found in 
the liver, but appreciable amounts can also be found in the kidney, brain, lungs, and 
adipose tissue.1,2,3 CDO has such a large impact on maintaining intracellular sulfur 
concentrations it can decrease steady state intracellular cysteine levels as well as 
glutathione levels.4 High levels of cysteine are associated with the neurological 
diseases Alzheimer’s and Parkinson’s diseases.5 Abnormal CDO activity and the 
accumulation of cysteine have been observed in patients suffering from the 
neurological disorder Hallervorden-Spatz syndrome.6 CDO may directly affect the 
disease cystinosis. Cystinosis occurs when cysteine builds up and it begins to form 
disulfide bonds with each other forming the insoluble compound cystine.7,8 CDO 
eliminates excess cysteine to avoid this condition.   
 
Figure 1.1. The conversion of cysteine to cysteine sulfinic (CSA) acid by CDO 
 
After CSA is made it can undergo two major pathways, one ultimately 
resulting in taurine formation and the other creating pyruvate and sulfate. The taurine 
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pathway involves the decarboxylation of CSA by the enzyme cysteine sulfinate 
decarboxylate to form hypotaurine (2-aminoethane sulfonate).9 Hypotaurine is then 
oxidized to taurine via a poorly understood pathway where enzymatic and non-
enzymatic mechanisms may occur.10 CSA can undergo a second pathways where 
transamination occurs to form β-sulfinylpyruvate, which spontaneously decomposes 
to sulfite and pyruvate.11 Sulfite readily oxidizes to sulfate. Lack of cellular sulfate 
has also been associated with rheumatoid arthritis.12
CDO is a Fe(II) non-heme iron dioxygenase and contains significant sequence 
homology with other members of the cupin superfamily of proteins.13 Members of 
this superfamily possess a ß-barrel with a jelly roll topology which can also be seen in the 
crystal structure (Figure 1.3).13 Members of this family contain two conserved sequence 
motifs, G(X)5H(X)H(X)3,4E(X)6G and G(X)5P(X)G(X)2H(X)3N (Figure 1.2), derived from the 
superfamily archetype, germin.14 The second sequence is less conserved than the first. The 
active site of these proteins are usually formed by a histidine and a carboxylate residue, either 
glutamate or aspartate, from the first motif and another histidine from the second motif 
forming the 2-his-1-carboxylate binding motif common among Cupin members. In CDO 
the carboxylate residue is replaced with another histidine forming a 3-histidine 
binding pocket.  
-35  MGSSHHHHHH SSGLVPRGSH MLEGWTEETR PSPAG                0 
1    MERTELLKPRTLADLIRILHELFAGDEVNVEEVQAVLEAYESNPAEWALY   50 
51   AKFDQYRYTRNLVDQGNGKFNLMILCWGEGHGSSIHDHTDSHCFLKLLQG  100 
101  NLKETLFDWPDKKSNEMIKKSERTLRENQCAYINDSIGLHRVENVSHTEP  150 
151  AVSLHLYSPPFDTCHAFDQRTGHKNKVTMTFHSKFGIRTPFTTSGSLENN  200 
Figure 1.2. Amino acid sequence of recombinant CDO. Residues -35 to 0 represent 
the 6x histidine tag used for purification. Residues in green are conserved residues 
through out other CDOs in other organisms near the metal binding site. Residues in 
red represent the three metal binding histidines. 
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 Figure 1.3. Crystal structure of rat CDO showing the typical jelly roll beta barrel. 
(PDB ID 2GH2) 
 
Four crystal structures of CDO have been resolved, three eukaryotic and one 
prokaryotic. These proteins came from mouse, rat, human, and Ralstonia eutropha 
(Figure 1.4).15,16,17,18 All the crystal structures show different binding geometries with 
different bound molecules but all contain the 3-histidine metal binding site. The 
mouse protein had nickel bound to the active site and was octahedral with the three 
histidines arranged as a facial triad with aqua molecules opposing them.15 Then the 
rat structure was modeled with an iron bound to one aqua ligand and the three 
histidines in a tetrahedral formation.16 The other two structures were modeled with 
iron and found to be 5-coordinate with a cysteine or two aqua molecules in the human 
and bacterial enzymes respectively.17,18  
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Figure 1.4. Metal binding sites of the four solved CDO crystal structures. (A) Mouse 
with Ni(II) bound (2ATF). (B) Rat with Fe(III) bound (2B5H). (C) Human with 
Fe(II) bound and cysteine in the binding site (2IC1). (D) The bacterial Ralstonia 
Eutropha with Fe(III) bound with a sulfate in the binding site (2GM6). 
 
The prokaryotic CDO also contains another unique feature from the other 
crystal structures. All but the bacterial structure reveals a novel cysteinyltyrosine 
cofactor. In the prokaryotic CDO the bridging cysteine is replaced by a glycine, 
disrupting the linkage.18 This linkage is well characterized in only one other enzyme, 
galactose oxidase. In galactose oxidase the linkage is required for enzyme 
functionality where it serves as an internal redox cofactor.19 Using site directed 
mutagenesis it was possible to convert cysteine-93 and tyrosine-157 to a serine and 
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phenylalanine respectively. With these mutations it is possible to study the 
importance of these residues and if the residues or the linkage between them are 
required for catalysis.  
Another novel feature of CDO is the 3-histidine metal binding site only shared 
by a few other members of the cupin superfamily such as diketone dioxygenase.20 
The more common 2-his-1-carboxyl binding motif is found amongst most of the 
Cupin superfamily. This motif is found to bind many more metals than iron while still 
yielding functional enzyme where as the 3-histidine motif does bind many various 
metals,20 but only when Fe(II) is bound to the active site is functional enzyme is 
yielded. Again, using site-directed mutagenesis the 2-his-1-carboxyl motif will be 
restored and its affects on CDO will be assessed. 
More insight into the mechanism and binding pocket of CDO is found by 
using x-ray spectroscopic techniques. Using extended x-ray absorption fine structure 
(EXAFS) it will be possible to see what geometry around the metal center is formed 
in unbound substrate, bound substrate, and bound with the activator cysteamine. It 
will give information about how the substrate binds whether it is by the carboxyl, 
amino, thiol or if the substrate is bound directly to the iron at all. The ligand distances 
around the iron will be found and used to determine possible functions of the various 
residues located around the metal.  
1.2 Experimental 
1.2.1 Over Expression in Escherichia Coli 
Recombinant rat CDO-ORF was previously subcloned into the vector pET-
14b and transferred into the E. Coli strain BL21(D3)pLysS. The cells are grown in 
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LB broth at 22 oC for 8 hours. At this time the expression of CDO is induced by 
addition of IPTG and ferrous ammonium sulfate to a final concentration of 200 μM 
each. Then the cells were grown for an additional 16 hours at 22 oC. 
Cells were harvested by centrifugation and resuspended in 50 mM Phosphate, 
pH 8.0, also containing 300mM sodium chloride buffer and 10 mM imidazole. This 
suspension is kept frozen in a –20 oC freezer for future analysis. The cells are lysed 
by thawing in the presence of phenylmethylsulfonyl fluoride (PMSF) and 
Benzonuclease. SDS-PAGE using the Laemmli method is used to confirm the 
expression of CDO.21  
1.2.2 Purification of Recombinant CDO 
The cell lysis is centrifuged to pellet the solid cell debris. The recombinant 
CDO contains an extra 35 amino acid his-tag sequence attached to the N-terminal end 
of the protein. The supernatant was ran over a nickel-nitrilotriacetic acid (NTA) 
column and the nickel will bind the his-tag of CDO purifying it from other impurities. 
The bound protein is washed with 1.5 L of 50 mM phosphate buffer, pH 8.0, 
containing 300mM sodium chloride and 30mM imidazole. After washing, the protein 
is eluted from the column with a 50mM phosphate buffer, pH 8.0, containing 300mM 
sodium chloride and 300mM imidazole. SDS-PAGE with the Laemmli method is 
used again to confirm that pure protein was eluted from column (Figure 1.5).21
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 Figure 1.5. SDS-PAGE gel after CDO purification. (Lane 1) Marker. (Lanes 2-7) 
elutions 1-6 from NTA column. (Lane 8) Cell lysis with CDO removed. The last 
marker represents 24 kDa. 
 
The elution is then concentrated with 10,000 Da cutoff 5 mL spin 
concentrators to a final protein concentration of approximately 100 μM and then 
buffer exchanged into 50 mM phosphate or HEPES buffer, pH 7.5 containing 100mM 
sodium chloride. The iron content of the sample is determined by ICP-OES in the 
same buffer and the final concentration of the sample is determined with bicinchonic 
acid (BCA) protein assay (Pierce).  
1.2.3 Activity Assay 
A water bath is preheated to 37oC. 1.5 mL centrifuge tubes (epi-tubes) were 
filled with varying substances depending on the test being performed. A standard test 
with CDO saturated for Vmax determination includes 50 μL of CDO and 950 μL of 30 
mM cysteine for final concentrations of 4.5 μM and 23.2 mM respectively. The tubes 
were incubated in the water bath for 3.5-5 hours. After this, the reactions were 
stopped by the addition of 20 μL of heptafluorobutyric acid (HFBA) to each epi-tube. 
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The HFBA causes the CDO to precipitate out of solution. The CDO was pelleted with 
centrifugation and the supernatant was aliquoted into a separate high performance 
liquid chromatography (HPLC) vial. Analyses of the samples were done in two ways, 
HPLC and induced coupled plasma with optical emission spectra (ICP-OES).22
1.2.4 Activity Analysis of CDO 
1.2.4.1 Use of High Performance Liquid Chromatograph (HPLC) 
The mobile phase that was used is a 99.4:0.6 (v/v) ratio of  water:methanol 
solution containing 3% HFBA. Flow conditions were 50 μL of sample injected at a 
flow rate of 0.8 mL/min for 20 minutes. Two Agilent C18 columns were used for 
separation. Detection of substances were done by the use of a ultra-violet light 
detector at the wavelengths 215nm and 230nm (Figure 1.6).22
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Figure 1.6. Activity assay chromatogram from HPLC. Absorption is at 215 nm. 
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1.2.4.2 Use of Induced coupled plasma with optical emissions spectra (ICP-OES) 
The same mobile phase for ICP-OES is used as in the HPLC analysis. Flow rate on 
the ICP-OES was set at 1 mL/min and was ran for 10 minutes. Only one Agilent C18 
column is needed for separation. The detector was set for a sulfur emission line at a 
wavelength of 181.975nm (Figure 1.7).  
 
Figure 1.7. Activity Assay chromatogram from ICP-OES. 
 
1.2.5 Cleavage of His-tag from Recombinant CDO 
Thrombin attached to agarose beads were washed three times with a 1x 
cleavage buffer (50 mM Tris-HCl, pH 8.0, 10 mM CaCl2) by using centrifugation and 
then decanting the supernatant. The CDO was buffer exchanged into 1x cleavage 
buffer. 1 mg of CDO was added to an epi-tube along with 100 μL of 10x cleavage 
buffer. This solution was diluted to 1 mL with DI water. The solution was placed on a 
rotating platform to flip and agitate the solution for 24 hrs. The cleaved protein was 
retrieved by the same method as the wash except the supernatant is decanted into a 
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separate epi-tube and stored at 4 oC. Confirmation of cleavage is done by SDS-PAGE 
looking for a band at 23 kDa.  
1.3 Results and Discussion 
 The expression of the recombinant enzyme was confirmed by SDS-PAGE. 
The SDS-PAGE clearly shows a thick band slightly above the 24 kDa marker. This 
band represents CDO with a histidine tag. The elution of CDO from the Ni-NTA 
column is done in six 10 mL aliquots. Most of the CDO is concentrated in the second 
aliquot, but reasonable amounts are distributed among the first, third, and fourth as 
well. (Figure 1.5) The purpose of the fifth and sixth aliquots is to make sure all CDO 
has been eluted. The gel also detects a high molecular weight peptide. It is unclear 
what this band is. The protein is still quite pure because the band is faint and does not 
represent much protein. It is possible that this peptide could represent the 68kDa sized 
CDO protein that was found by Waring and co-workers. This protein found by 
Waring did not dissociate under reducing conditions with SDS or with boiling.23,24  
 The eluted protein is concentrated using 10 kDa spin concentrators. Then it is 
buffer exchanged. At first a phosphate buffer pH 7.5 containing 100mM sodium 
chloride was used because it was most stable in that buffer but then it was found to be 
also stable in HEPES buffer pH 7.5 containing 100mM sodium chloride, so HEPES 
buffer was then used. HEPES buffer was chosen over phosphate buffer because of the 
convenience for metalation and thrombin cleavage. The samples of protein come out 
to an approximate volume of 2 mL and concentration of 100 μM per liter of culture. 
This varies from purification to purification. The sample is tested for activity, which 
can be seen in the chromatograms above (Figure 1.6 and 1.7). Iron content of the 
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CDO samples have an average of 10%, but have been as low as 6%. Recently it was 
possible to incorporate 26% iron into the enzyme using a slightly modified metalation 
scheme by ripping out other metals by chelation with EDTA and adding iron 
ammonium sulfate to the final purified product under anaerobic conditions  
 When enzyme is confirmed for purity and activity it may be cleaved to 
remove the histidine-tag. The purpose of this is to increase maximum concentration 
that CDO can achieve without precipitating out of solution. Increased concentrations 
are needed for several of the following experiments described later such as X-ray 
Absorption Spectra (XAS). Also thrombin cleavage is needed to prepare enzyme for 
crystallization because the native enzyme is needed. 
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CHAPTER 2 
MUTATION OF THE CYSTEINLYTYROSINE COFACTOR IN CYSTEINE 
DIOXYGENASE 
2.1 Introduction 
One class of enzyme cofactors arises from covalent modifications of amino 
acid side chains. A common example of this is a disulfide bond between two 
cysteines due to the spontaneous oxidation of the thiol in the presence of oxygen. 
There are other examples of covalent cofactors but are usually rare. These include the 
cysteinyltyrosine thioether bond in galactose oxidase, tyrosine-histidine bond in 
cytochrome C oxidase, tryptophan-tryptophan bond in methylamine dehydrogenase, 
histidine-cysteine bridge in catechol oxidase, and 2,4,5-trihydroxyphenylalanine 
quinine in copper amine oxidase.1,2,3,4,5 All of the cofactors in these enzymes serve as 
redox active amino acids.6
 
Figure 2.1. The metal binding site with iron bound, but clearly showing the 
cysteinyltyrosine cofactor on the upper left.  
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As mentioned before, in section 1.1, four crystal structures have been solved 
and three of the four contain a cysteinyltyrosine cofactor (Figure 2.1), this puts CDO 
into a short list of enzymes that contain cofactors.7,8,9 This thioether cofactor is very 
rare and is only well characterized in one other enzyme, galactose oxidase (Figure 
2.2).10 It is thought it is also present in glyoxal oxidase, but is only characterized 
through resonance Raman spectroscopy and optical absorption spectra.11 In galactose 
oxidase, the cofactor is redox active and a copper ligand.10 The bridging bond is a 
post-translational modification. It has been shown that if this modification does not 
occur, the enzyme is non-functional.10
 
Figure 2.2 Metal Binding site of galactose oxidase. The copper is bound by Tyr272, 
Tyr495, His496, and His581. Tyr272 is also involved in a thioether bond with 
Cys228. 
 
 It is possible that the cofactor in CDO serves a purpose similar to that of 
galactose oxidase. It is believed that the cofactor most likely does not serve as a 
reducing agent because the cysteinyltyrosine does not exist in the bacterial CDO 
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crystal structure, where the cysteine is replaced by a glycine.12 Thus, despite the lack 
of the cofactor, the enzyme is able to function as a dioxygenase. Instead the 
cysteinyltyrosine may serve as an intermediate stabilizer during the reaction 
mechanism through hydrogen bonding. The following mutagenesis experiments were 
performed to determine the function of the cofactor and help characterize CDO’s 
mechanism and unique structure.  
2.2 Experimental 
2.2.1 Mutation of the Cysteinyltyrosine Cofactor 
Two mutations were done for the characterization of cysteinlytyrosine. These 
mutations were C93S and Y157F. They were made using site-directed mutagenesis. 
The DNA plasmid, pET-14b containing the recombinant rat CDO-ORF, was isolated 
from E. Coli BL21(D3)pLysS cells that contained it using a miniprep assay (Qiagen). 
Reverse transcription polymerase chain reaction was performed using the respective 
primers for each mutation (Table 2.1). Confirmation of the mutation was performed 
by DNA sequencing obtained at Keck laboratory in Yale. When the mutation was 
confirmed, the mutated plasmid was transformed into the super-competent cell line, 
Nova Blue, and plated on LB containing ampicillin. 
Table 2.1. Primer sequence for the cysteinyltyrosine cofactor mutations 
Mutation Forward Primer Reverse Primer 
C93S 3’-cac acg gac tcc cac tcc ttt ttg 
aag ctg ctg-5’ 
3’-cag cag ctt caa aaa gga gtg gga 
gtc cgt gtg-5’ 
Y157F 3’-gtg agc ctt cac ttg ttc agt cca 
cct ttc gat ac-5’ 
3’-gt atc gaa agg tgg act gaa caa gtg 
aag gct cac-5’ 
A culture of Nova Blue cells were grown in LB broth containing ampicillin 
overnight and subsequently pelleted and miniprepped. The DNA from the miniprep 
was transformed into BL21(D3)pLysS cells and plated. Finally overnight cultures 
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were grown in LB broth containing ampicillin and chloramphenicol and then samples 
were flash frozen in cryogenic tubes with liquid nitrogen and stored in a -80oC freezer 
as a cell stock.  
2.2.2 Michaelis Menten Kinetics of the Mutants 
 Assay conditions similar to those of the standard activity assay described in 
section 1.2.3 were used to assay the mutant enzymes. Eight reactions were performed 
per mutant with the cysteine concentrations varying from 0-23mM. Assays are 
analyzed as described above in section 1.2.4 and the results are plotted with cysteine 
versus enzyme activity. 
2.3 Results 
Two mutations were made to test the importance of the cysteinyltyrosine 
cofactor, C93S and Y157F. Both of these mutations disrupt the covalent bond and 
were chosen because the residues best replace the existing residues in terms of size 
and chemistry. Figure 2.3 shows the results plotted as a Michaelis Menten graph, 
which then can be seen summarized in table 2.2. The activity is normalized to iron 
content because enzyme is only active when iron is incorporated in the active site. 
Since CDO only binds about 10% and that number varies from samples to sample, 
each of the activities need to be normalized to get the true activity.  
Table 2.2. Table of activities for cysteinyltyrosine mutants normalized to iron 
content. 
Sample Activity (mol 
CSA/min/mol Fe) 
Percent Activity 
(compared to wild 
type) 
Km (mM) kcat/Km  
(M-1 s-1) 
Wild Type 41.8±7.3 100% 1.8±0.2 1.3E3±0.5 
C93S 23.9±4.5 57.2% 1.6±0.2 7.8E2±0.5 
Y157F 3.4±0.3 8.1% .17±0.01 1.0E3±0.3 
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Figure 2.3. Michaelis Menten graph of cysteinyltyrosine mutants. 
 
2.4 Discussion 
The results show that the cysteinyltyrosine is not required for activity in 
context to its role in galactose oxidase. In galactose oxidase if the cofactor is 
disrupted in any way then the enzyme is no longer active.10 In CDO, the elimination 
of the cofactor in the C93S mutant caused a decrease in activity of 42.8%. Also 
Y157F, which changed the residue closest to the metal center, still had 8.1% activity. 
Although this is a significant drop in activity, it proves that the cofactor is not 
required for activity. Instead each of the residues involved serve different purposes.  
The large drop in activity due to the loss of the tyrosine may suggest that it is 
involved in forming the enzyme substrate complex. The hydroxyl group may serve as 
a hydrogen bond donor or proton donor to help stabilize the intermediates. The 
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cysteine has a less important role. The cofactor provided by the cysteine appears to be 
merely a stabilizing bridge for the more important tyrosine. When the cysteine is 
removed, the cofactor breaks and the tyrosine is less rigid. Less rigidity means that 
the tyrosine can move and “flop” around causing it to adopt conformations that some 
of the time don’t stabilize the intermediates, thus the reaction goes slower. The 
function of the cysteine would then be to hold the tyrosine in place. This forces the 
hydroxyl group to point directly to a pocket in the metal center where the substrate 
may bind.  
The less crucial role of the cysteine explains why it doesn’t exist in the 
bacterial enzyme but the tyrosine does. The reason for this evolutionary difference in 
enzyme structure maybe because full activity of the enzyme is not needed. Having the 
fully functional enzyme as it exists in mammals may be detrimental to the bacteria 
because too much cysteine would be converted to CSA leaving too little for other 
functions such as other protein expression. For the bacterial enzyme from Ralstonia 
eurtropha, the tyrosine by it self has enough activity for its function.  
Overall the characterization of the cysteinyltyrosine cofactor gives some 
insight into the mechanism of the reaction and more information on how the 
oxygenases of the cupin superfamily function. 
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CHAPTER 3 
PROBING THE 2-HISTIDINE-1-CARBOXYLATE MOTIF OF THE CUPIN 
SUPERFAMILY 
3.1 Introduction 
 As mentioned above, the cupin super family typically contains a 2-histidine-1-
carboxylate motif, but there are variations to this.1 For instance, Quercetin 
Dioxygenase (QDO) contains a 3-histidine-1-carboxlyate binding pocket.2 Most 
importantly to this thesis is the 3-histidine motif of CDO. It has been shown that most 
non-heme iron oxygenases of the 2-histidine-1-carboxylate motif also require α-
ketoglutarate as a co-substrate.3 α-ketoglutarate acts as a co-substrate and accepts one 
of the oxygen atoms and decomposes to carbon dioxide and succinate.3 This is 
coupled with the oxidation of the main substrate.3 These α-ketoglutarate dependent 
enzymes catalyze a diverse amount of reactions like side-chain modifications, 
DNA/RNA repair, metabolism, and degredation of many compounds.3  
 The source of power for the catalysis of these reactions is believed to come 
from oxygen activation.4 Here it is hoped to elucidate the mechanism by which CDO 
catalyzes its reaction. CDO is not a α-ketoglutarate dependent oxygenase and it 
contains a unique binding pocket. The differences in CDO compared to the other 
members of the cupin superfamily suggest it reacts differently. This means there are 
no significant clues into how the mechanism of CDO works. Also the sulfur on the 
cysteine readily oxidizes; this suggests that the sulfur does not need a strong 
oxidizing agent for the reaction to occur.  
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 The following experiments hope to elucidate some of the mechanism by 
mutating one of the histidines in the binding pocket to a carboxylic amino acid. The 
carboxyl group of the amino acid should provide the iron atom with more oxygen 
activating potential. If CDO undergoes oxygen activation as a part of its mechanism, 
then CDO should still be able to catalyze its reaction.  
3.2 Experimental 
3.2.1 Creating the 2-Histidine-1-Carboxylate motif through mutation 
 Site-directed mutagenesis is performed using the same protocol as described 
in chapter 3 when creating the cysteinyltyrosine mutations. In the cysteinyltyrosine 
mutants it was possible to use the mixture of pLysS and pET-14b vectors. The pET-
14b vector contains the CDO-ORF and the pLysS vector comes in all the 
BL21(D3)pLysS cells. In the case of H140D the RT-PCR did not work with the 
mixture, so the pET-14b vector which contained the CDO-ORF had to be purified 
alone.  
To do this DNA purification, both plasmids were isolated using the “DNA 
miniprep kit” (Qiagen) from frozen cell stocks of BL21(D3)pLysS cells containing 
the pET-14b vector. The plasmid mixture was transformed into Nova Blue cells and 
grown on LB plates with ampicillin. The controls were cells grown on plates with no 
drugs and plates with ampicillin and chloramphenicol. A colony from the ampicillin 
only plate is taken and a 5 mL overnight culture was made. This DNA from the 
culture was isolated and the procedure was repeated. This was repeated until colonies 
grow on the ampicillin plate and no drug plate but not the ampicillin and 
chloramphenicol. When the colony no longer grows on the dual drug plate, then the 
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colonies on the ampicillin-only plate contained the pET-14b vector and not the pLysS 
vector. 
After the pET-14b vector is purified then the mutagenesis can be performed as 
described above in chapter 3. The forward primer for H140D is 3’-gat tct att ggc tta 
gat cga gta gag aac gtc agc c-5’ and the reverse primer is 3’-g gct gac gtt ctc tac tcg 
atc taa gcc aat aga atc-5’. 
3.2.2 Characterizing H140D 
3.2.2.1 Activity analysis 
 Assay is conducted as the standard assay described above. 50 μL of H140D 
CDO is added to an epi-tube to a final concentration of 4.9 μM after the addition of 
cysteine. 950 μL of Cysteine is also added for a final concentration of 18.7 mM and 
total volume of 1 mL. 
3.2.2.2 Metal analysis 
 Metal analysis was performed on an ICP-OES. Samples were injected into the 
nebulizer and analyzed for iron content at the wavelength 238.208 nm. Iron content 
was then compared to protein concentration to obtain percent iron content. 
3.3 Results 
H140D was created as the first of three of mutations of the metal binding site 
that will mimic the 2-his-1-carboxylate motif. This is important because most of the 
other members of the cupin super family have a 2-his-1-carboxylate motif. The 
results from this mutation showed that H140D is required for activity and replacing it 
with an aspartate kills activity. It can be seen in the chromatogram below that H140D 
lacks the CSA peak (Figure 3.1).  
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Figure 3.1. HPLC chromatogram with UV detection at 215 nm. The H140D 
chromatogram clearly shows no CSA peak is present, whereas wild type CDO does 
have a CSA peak.  
 
3.4 Discussion 
To begin the characterization of H140D it was first analyzed for activity. 
When looking at the HPLC chromatogram it can be easily seen that no CSA is 
produced under conditions where WT does have product. This peak normally elutes 
at around 6.5 minutes. If CSA is formed, it is due to the spontaneous oxidation of the 
thiol of cysteine naturally. This amount of CSA that is naturally formed under these 
conditions is not detectable. H140D binds approximately 7% ferrous, so it is known 
that the lack of activity is not caused by the lack of iron incorporation. 
Since the mutant was found to be inactive it suggests that CDO may not 
undergo oxygen activation. The reasoning behind this theory is supported by the fact 
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that when the carboxylate is introduced into the metal binding center it would add 
more electron density to the iron. This would cause more oxygen activating potential 
for the iron. If the mechanism of the CDO reaction goes via oxygen activation then 
the addition of the carboxylate might increase enzyme activity instead of killing it. 
Also in nature the thiol of the cysteine substrate becomes oxidized very easily and in 
fact CSA is formed naturally as mentioned before. Usually the oxidation of the thiol 
results in a disulfide bond with another cysteine, forming cystine. Since the thiol 
oxidizes easily, oxygen activation is not necessarily needed to perform the reaction 
that CDO catalyzes. Thus, CDO is present for a different reason other than activating 
oxygen for attack on cysteine.  
It is possible that since CDO has a unique binding pocket that it also reacts 
uniquely. Since CDO does not use oxygen activation it is possible that CDO may 
react via a substrate activating pathway where a sulfur radical develops and attacks 
the oxygen to form the sulfur-peroxo intermediate. 
Next step for characterization of H140D requires a return to Stanford for XAS 
analysis. Samples have been prepared but yet to be analyzed due to time constraints 
on the beam line.  
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CHAPTER 4 
XAS STUDIES OF THE METAL BINDING SITE OF CYSTEINE 
DIOXYGENASE 
4.1 Introduction to XAS Techniques  
 X-ray absorption spectroscopic (XAS) techniques are used to determine the 
local structure of the metal site. The two specific regions of the XAS spectra that 
were used in this study were extended x-ray absorption fine structure (EXAFS) and x-
ray absorption near edge spectra (XANES). Each spectrum tells a different story. 
Coordination number and geometry can be determined by XANES analysis of 
features found below the edge energy. EXAFS is found above the edge and can be 
used to determine bond lengths and what type of atom the metal is bonded to. 
 The theory behind XANES involves an x-ray tuned to the absorption energy 
of the core electron of the element being analyzed. The atom absorbs the x-ray and a 
core electron is excited. The edge corresponds to the energy at which the electron is 
ejected. This is referred to as the white line. Pre-edge features correspond to high-
energy electron transitions such as a 1s→3d transition. The area of this peak contains 
information on what the coordination geometry of the target atom maybe.1
 The EXAFS region begins at about 200eV above the edge. The ejected 
photoelectron has inherent wave properties that give rise to constructive and 
destructive interference with photoelectron waves that are backscattered from nearby 
atoms.1 Using the equation below it is possible to extrapolate information about the 
metal center of the enzyme from the EXAFS.2 Figure 4.1 outlines what information 
comes from which parts of the EXAFS more simply.2
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Table 4.1 Variables and their meanings to the equation above 
Variable Meaning 
Ns Number of scattering atoms in the shell 
| fs(π,k) | Inherent backscattering amplitude for this type of scattering atom 
Ras Distance between absorbing atom and the scattering atoms in this 
shell (Å) 
λf Mean free path for inelastic scattering of photo electrons (Å) 
σas2 The rms deviation of Rasexp(-2 σas2k2) is referred to as the Debye-
Waller factor 
αas(k) The inherent backscattering phase shift for this 
absorbing/scattering atom combination. 
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Figure 4.1 Simplified outline of EXAFS features and the information obtained from 
them. 
 
 XAS is typically done at synchrotron sources because a variable x-ray source 
is needed as well as high intensities. Several are located around the world. The CDO 
XAS experiments were performed at Stanford University using the SSRL beam-line 
9-3.  
4.2 Experimental 
4.2.1 XAS sample preparation 
Sample preparation was done in anaerobic conditions. The thrombin cleaved 
CDO from the protocol in section 1.2.5 was reconstituted with Fe (II) ammonium 
sulfate. The CDO is in 50mM HEPES, pH 7.5 and contains 100 mM NaCl. EDTA 
was added to the sample of CDO and allowed to sit for one hour before being 
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removed by buffer exchange. Iron was added to a final concentration that was twice 
that of the concentration of CDO and allowed to sit for 2 hours and then chelexed and 
buffer exchanged to remove excess iron. The CDO was 217 μM and thus the final 
concentration of iron during reconstitution was 434 μM. The CDO was then 
concentrated to 500 μM. 
 30 μL of the CDO is aliquoted into an epi-tube with 1 μL of a 62 mM 
solution of cysteine for a final concentration of 2 mM cysteine. Another sample 
prepared with just the activator, cysteamine, was made the same way but with a 62 
mM solution of cysteamine. A control sample was also made without substrate or 
activator. Sample analysis was performed at Stanford University at the SSRL beam 
line 9-3. Other iron samples that were made for a second trip to the beam line include 
the mutant H140D and H140D with cysteine. These samples were prepared using 
cleaved H140D CDO and used the same procedures as above except using mutant 
cleaved CDO instead. Some nickel samples were also prepared by using nickel 
chloride in place of the ferrous ammonium sulfate during metal reconstitution. These 
samples include Ni-CDO and Ni-CDO with cysteine. Metal content was determined 
after samples were analyzed by XAS. This is done on the ICP-OES  
4.2.2 XAS analysis methods 
Sample analysis was performed at Stanford University at the SSRL beam line 
9-3. Analysis was done at 10 K using a liquid helium cryostat. The ring conditions 
were 3 GeV and 80-100 mA. The optics consisted of a Si(220) double-crystal 
monochromator and two rhodium coated mirrors. A flat mirror before the 
monochromator was used for harmonic rejection and vertical collimation, and a 
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toroidal mirror after the monochromator was for focusing. The detector at this 
beamline was a 30-element germanium detector (Canberra). A set of soller slits with a 
Z-1 element filter was placed between the sample chamber and detector to minimize 
scattering. XANES was collected from ±200 eV relative to the edge. EXAFS was 
collected from 13.5-16 K above the edge energy.3  
4.3 Results  
The EXAFS that was obtained from the beam trip did not have good enough 
signal to noise ratio for analysis due to low metalated CDO concentration. However, 
there was some useful data obtained from the XANES spectra. It can be seen that the 
sample that contained the activator cysteamine was very different than the CDO 
sample and the CDO with substrate sample. The differences can be seen in the 1s → 
3d transition peak area as well as the white line intensity at approximately 7135 eV 
(figure 4.2). 
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Figure 4.2  XANES spectra clearly showing large differences in 1s → 3d and edge 
peak intensities. 
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To ensure that metal concentrations are high enough for analysis by XAS, 
metal analysis was done on the samples post analysis. The metal content of the 
samples that were analyzed were all 12% of enzyme had iron bound. This means that 
the iron concentration was approximately 60 μM because the protein was 500 μM. 
Metal analysis on samples that were not analyzed by XAS was not performed yet. 
There is a limited amount of protein when making samples due to low protein 
expression and slow protein cleavage thus all protein that is cleaved is used to make 
samples. Only after the samples are analyzed by XAS then can be used to determine 
metal analysis because samples are not retrievable after analysis with ICP-OES. 
4.4 Discussion 
To further elucidate the coordination number and binding geometry of the 
metal binding site of CDO, the power of x-ray absorption spectroscopy was used. The 
purpose of the technique was to determine the geometry of the binding site, what 
ligands bind the iron center, and their distances from the iron. When looking at the 
results for the three samples that were analyzed it can be seen easily that the 
cysteamine XANES is quite different than the other two. The enzyme and the 
enzyme/substrate complex look very similar which confers with prior results obtained 
previously.  Also it was previously found that the substrate does not bind by the thiol. 
It is suggested that the substrate may not bind to the iron at all, which is supported by 
the results since there is so little change in the XANES spectra.  
Unfortunately no conclusive data can be determined from the EXAFS of the 
three samples. There was a great amount of noise past 3.5 Å and it is unclear what 
peaks were noise and what may be data. Previous experiments by a former student 
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showed similar XANES spectra and the EXAFS from these showed six N/O ligands 
on samples of CDO without cysteine and CDO with cysteine (figure 4.3)4. 
 
Figure 4.3. EXAFS and XANES of CDO without cysteine (A, solid line) and with 
cysteine (B, dotted line) showing a white line around 7128 eV. The Fourier transform 
show 6 N/O donors on both samples.4
 
More samples of for XAS analysis were made but due to time constraints they 
were not analyzed. The unique mutant H140D was made to probe the metal binding 
site and to see if there is a change in binding coordination from wild-type CDO. 
H140D is the first of a series of mutants made to mimic the 2-histidine-1-carboxylate 
motif that most other members of the cupin superfamily of oxygenases. This motif is 
interesting because most other members with this motif also require α-ketoglutarate 
where it acts as a reducing agent. Also these enzymes with the 2-histidine-1-
carboxylate motif undergo oxygen activation. Nickel samples were also made and not 
analyzed. These include nickelated CDO and nickelated CDO with cysteine bound. 
The purposes of these were to see if nickel changes the coordination number and 
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geometry of the metal binding site. Also to see if there are any changes in the way the 
substrate may bind to this alternate although non-active metal.  
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CHAPTER 5 
CDO ACTIVITY INHIBITORS REVISISTED 
5.1 Introduction 
 Sergio Chai, a former student of the lab, tested several compounds to see their 
effect on CDO activity. Some of these compounds were found to be inhibitors of 
CDO. These included homocysteine, mercaptopropionic acid, aspartic acid, α-
ketoglutarate, and S-carboxymethyl-cysteine.1 The common factor between these 
compounds is that they are structural analogs of cysteine and also contain a 
negatively charged side chain.1 Other compounds were tested that did not have 
negative side chains and were not found to be inhibitors.1
 CDO was the first non-heme iron dioxygenase that was discovered to be 
inhibited by α-ketoglutarate. In fact other non-heme iron dioxygenases use α-
ketoglutarate as a co-substrate.2 These oxygenases are known as intermolecular 
dioxygenases where one oxygen atom is inserted into the substrate and the other 
oxygen is added to the α-ketoglutarate.2 It is clear that CDO is not an intermolecular 
dioxygenase because it utilizes both oxygen atoms in its reaction.  
 In this chapter we will be revisiting the inhibitors that were tested previously. 
It was found that aspartate in particular inhibited CDO by about 50%. The previous 
inhibition experiments were conducted in phosphate buffer (50 mM phosphate pH 
7.5, 100 mM NaCl). Also as well as phosphate, ammonium acetate solution (50 mM 
ammonium acetate, pH 7.5, 100 mM NaCl) was also used for other experiments. As 
mentioned before, experiments have changed to be conducted in HEPES buffer (50 
mM Hepes, pH 7.5, 100 mM NaCl) due to solubility problems when using phosphate 
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buffer. Phosphate salts are insoluble when they form the compounds ferrous 
phosphate and calcium phosphate. 
 Retesting of aspartate as an inhibitor was needed to determine what class of 
inhibitor it was. This experiment was conducted in HEPES buffer instead of 
phosphate buffer and a surprising result occurred. Aspartate caused an increase in 
CDO activity instead of inhibiting it. These results stimulated new experiments to 
elucidate why aspartate acts as an inhibitor in phosphate buffer but an activator in 
HEPES buffer.  
5.2 Experimental  
5.2.1 Aspartate inhibition assay 
 This was an assay to determine what type of inhibitor aspartate was. The assay 
conditions used HEPES buffer (50 mM HEPES, pH 7.5, 100 mM NaCl). The controls 
had no inhibitor added to the reactions. 50 μL of 62 μM CDO was diluted with 
HEPES buffer with cysteine. The cysteine concentration varied from 0 mM to 13.9 
mM over eight reactions. There were two tests done, one with aspartate as the 
inhibitor and one with acetate as another inhibitor. These tests had the same CDO and 
cysteine concentrations but also added were the inhibitors to their respective reactions 
to a final concentration of 9 mM. Reactions were incubated for about 3 hours and 50 
minutes. Assays were analyzed on the HPLC as the protocol stated above in section 
1.2.3.1. 
5.2.2 Buffer inhibition assay 
CDO was buffer exchanged into phosphate buffer, ammonium acetate 
solution, and HEPES buffer. Two 50 μL aliquots per buffer were added to epi-tubes 
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totaling six samples. The samples were reacted and analyzed as stated in the activity 
assay protocol above (Section 1.2.4.1) except that aspartate is also added to one of the 
tubes per buffer at a final concentration of 2mM.  
5.2.3 Metal chelation by aspartate 
CDO at a concentration of 200 μM was taken and aliquoted into three 6 mL 
volumes. These were buffer exchanged into the three different solutions. The 
solutions were phosphate buffer, ammonium acetate solution, and HEPES buffer. 
Each of these buffers was 50 mM, pH 7.5 and also contained 100mM NaCl. They 
were buffer exchanged and concentrated using 10,000 Da spin concentrators down to 
a final volume of 2 mL. After buffer exchanging the three samples were each split 
into two aliquots and added to epi-tubes. To one aliquot of each buffer sample, 
aspartic acid was added to a final concentration of 2 mM. These were incubated for 
15 minutes at room temperature. The six samples were then buffer exchanged into 
their respective buffers to remove any aspartic acid and unbound metal. The samples 
were then analyzed for iron content on an ICP-OES.  
5.2.4 Retesting of previously found inhibitors in HEPES buffer 
A selection of the previously investigated inhibitors were experimented in 
HEPES buffer. The compounds selected were homocysteine, α-ketoglutarate, and S-
carboxymethyl-cysteine. The reaction conditions 500 μL of 30 mM cysteine and 450 
μL of 30 mM inhibitor were added to 50 μL of CDO. The assay conditions were the 
same as previously said above by incubation in 37 oC water bath for 4 hours.  
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5.3 Results 
A number of different buffers were used through out the experiments during 
the studying of CDO by the current student as well as previous students. The three 
solutions were phosphate, ammonium acetate solution, and HEPES. All of them were 
pH 7.5 and also contained 100mM NaCl. The effect of the buffer was put into 
question when it was found that in HEPES, aspartic acid acted as an activator. This 
was odd because it was previously found previously that aspartic acid was an 
inhibitor.1 The experiments that found that aspartic acid was an inhibitor utilized the 
phosphate buffer.  
The aspartate inhibition assay was conducted to determine what type of 
inhibitor it was. The results of the assay concluded that aspartate was in fact an 
activator instead of inhibitor. Aspartate at high concentrations of cysteine increased 
activity by approximately 8% compared to wild type CDO without aspartate. The 
acetate portion of this assay inhibited CDO by approximately 40%.  
When assays were conducted in the various buffers stated above it was found 
that in HEPES aspartic acid actually acts as a slight activator. It increased activity by 
8%. In phosphate and ammonium acetate solution aspartic acid was found to be an 
inhibitor. Aspartic acid inhibited activity by 18% and 63% in phosphate buffer and 
ammonium acetate solution respectively. It was thought that aspartate may be 
chelating the iron and extracting it out of CDO. The results from the metal analysis 
from the chelating experiment found that the samples of CDO in HEPES buffer 
contained 14.9% iron and 15.9% with aspartate. CDO in phosphate buffer and 
ammonium acetate solution had a decrease in iron content when aspartate was added 
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from 14.5% to 12.3% and 14.3% to 7.0%. This correlates to an increase in iron in 
HEPES buffer by 6.7% and a decrease by phosphate buffer and ammonium acetate 
solution by 15.1% and 51.0% respectively. 
Several compounds that were previously found to be inhibitors were retested 
in HEPES buffer. The various compounds tested and found to be inhibitors were 
homocysteine, mercaptopropionic acid, aspartic acid, α-ketoglutarate, and S-
carboxymethyl-cysteine. These inhibition assays were performed in phosphate buffer. 
In the retest it was found that homocysteine, S-carboxymethyl-cysteine, and α-
ketoglutarate had an increase in activity by 26.1%, 43.4%, 44.2% respectively when 
compared to wild type CDO with just cysteine present. The rates and their percent 
activities compared to wild type CDO with no activator/inhibitor added can be seen in 
table 5.1. Cysteamine caused no appreciable increase or decrease in activity.  
Table 5.1. Activity increases exhibited by CDO with various activators in HEPES 
buffer, pH 7.5 
Retested 
activators/inhibitors 
Rates (mol CSA/min) Percent activity (Compared to 
Wild type) 
No activator/inhibitor 38.2±7.2 100% 
Homocysteine 48.2±6.5 126.1% 
S-carboxymethyl-
cysteine 
54.8±9.3 143.4% 
α-ketoglutarate 55.1±8.6 144.2% 
 
5.4 Discussion 
In the past it was determined that structural analogs of cysteine with a 
negative side chain had the ability to inhibit CDO activity. In various tests that were 
conducted recently it appears that these analogs may not be inhibitors. In fact they 
activated CDO. A reexamination of the inhibitor aspartate was performed to 
determine what type of inhibitor it was. These experiments revealed that aspartate is 
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an activator in the HEPES buffer, pH 7.5. Then another test, the buffer inhibition test, 
confirmed that aspartate is an activator in HEPES, but it is also an inhibitor in 
phosphate buffer and ammonium acetate solution. 
At first this was confusing because there weren’t many indications of what 
could be happening chemically. Then it was thought that aspartate could be chelating 
the metal and facilitating removal from the enzyme. After the metal is pulled out the 
phosphate or acetate can bind to it and keep it from loading back into the enzyme. 
The negative charges on the ions have the ability to ligate the metal.  
To test this theory the aspartate chelating experiment was done. The enzyme 
was incubated with aspartate in phosphate buffer to rip out the metal and then buffer 
exchanged for metal analysis. This was compared to enzyme that was not subjected to 
aspartate. The findings support that aspartate may be facilitating iron removal and 
then the ligation by phosphate keeps it from reentering the binding site.  
As stated above in the results section it was found that the addition of 
aspartate to HEPES buffer increased the iron content from 14.9% to 15.9%. In the 
other two buffers the aspartate caused a drop in iron from 14.5% to 12.3% and 14.3% 
to 7.0% in the phosphate and acetate buffers respectively. This correlated to an 
increase in iron in HEPES buffer by 6.7% and a decrease by phosphate and acetate 
buffers by 15.1% and 51.0% respectively. These percentages are very similar to that 
of the changes in activity. In HEPES buffer the aspartate caused an increase of 8% 
and a decrease of 18% and 63% in phosphate and acetate respectively. These results 
support the hypothesis that aspartate aids in iron removal from CDO in phosphate and 
acetate buffers illustrated in figure 5.1. Thus, when the samples were buffer 
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exchanged the metal bound to aspartate and the ion could be washed out lowering the 
amount of metal in solution. In the case of phosphate it is possible that the metal was 
also removed via precipitation due to the insolubility of iron (II) phosphate. 
Fe-CDO Fe + CDO
Fe Complex + CDO
Aspartate with
Acetate or Phosphate
 
Figure 5.1 Iron equilibrium when aspartate is introduced into reaction. 
Metal loading of the enzyme was previously done in ammonium acetate 
buffer because iron (II) phosphate would form in the phosphate buffer and it is 
insoluble, but because ammonium acetate is not truly a buffer at pH 7.5 it was still not 
preferred. Thus, HEPES buffer is currently used to load the enzyme with iron.  
Then there is the question of whether the other previously found inhibitors 
were in fact still inhibitors in HEPES buffer. Thus, the purpose of the retesting was to 
determine if the inhibitors found previously are infact still inhibitors in the HEPES 
buffer. These compounds are structural analogs of cysteine and also contain a 
negative side chain. It was found that structural analogs without the negative side 
chain had no affect on CDO activity. In the retesting it was found that the structural 
analogs that were once inhibitors actually had activating qualities in the HEPES 
buffer. α-ketoglutarate had the largest increase in activity but S-carboxymethyl-
cysteine follows closely behind by about one percent.  
The activation of CDO by these cysteine analogs gives clues into how the 
reaction mechanism occurs. One hypothesis is that multiple cysteine molecules 
maybe bound in the active center and the cysteine that is actually converted to CSA 
 40
may not be bound directly to the iron. One cysteine is bound to the iron and the 
cysteine that is reacted with oxygen is apart of a hydrogen-bonding network with 
various residues and the cysteine bound to the iron. The activating compounds with 
the negative side chains may be able to find its way into the active site and bind to the 
iron more tightly than cysteine. Thus the reaction can occur more quickly when these 
activators are present.  
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